Abzena PLC Annual Report and Accounts (8818R)
19 June 2018 - 9:28PM
UK Regulatory
TIDMABZA
RNS Number : 8818R
Abzena PLC
19 June 2018
Abzena plc
Annual Report and Accounts for the Year Ended 31 March 2018
Cambridge, UK, 19 June 2018 - Abzena plc (AIM: ABZA, 'Abzena' or
the 'Group'), the life sciences group providing services and
technologies enabling the development and manufacture of
biopharmaceutical products, announces that its Annual Report and
Accounts for the year ended 31 March 2018, is now available on the
"Investors" section of the Group's website at
http://www.abzena.com/about/investor-information/results-presentations/
Printed copies of the Annual Report and Accounts are available
from the Company Secretary, Abzena plc, Babraham Research Campus,
Babraham, Cambridge CB22 3AT, UK.
-Ends-
Enquiries:
Abzena plc
John Burt, Chief Executive Officer +44 1223 903498
Numis (Nominated Adviser and Broker)
Clare Terlouw / James Black / Paul Gillam +44 20 7260 1000
N+1 Singer (Joint Broker)
Aubrey Powell / Liz Yong +44 20 7496 3000
Instinctif Partners +44 20 7457 2020
Melanie Toyne Sewell / Rozi Morris / abzena@instinctif.com
Alex Shaw
Notes to Editors
About Abzena
Abzena (AIM: ABZA) provides proprietary technologies and
complementary services to enable the development and manufacture of
biopharmaceutical products.
The term 'ABZENA Inside' is used by Abzena to describe products
that have been created using its proprietary technologies and are
being developed by its partners, and include Composite Human
Antibodies(TM) and ThioBridge(TM) Antibody Drug Conjugates (ADCs).
Abzena has the potential to earn future licence fees, milestone
payments and/or royalties on ABZENA Inside products.
Abzena offers the following services and technologies across its
principal sites in Cambridge (UK), San Diego, California (USA) and
Bristol, Pennsylvania (USA):
-- Biology research studies, including immunogenicity assessment
of candidate biopharmaceutical products and bioassay
development;
-- Protein engineering to create humanized antibodies and deimmunised therapeutic proteins;
-- Cell line development for the manufacture of recombinant proteins and antibodies;
-- Contract process development and GMP manufacture of
biopharmaceuticals, including monoclonal antibodies and recombinant
proteins for preclinical and clinical studies;
-- Contract synthetic chemistry and bioconjugation research
services, focused on antibody-drug conjugates (ADCs);
-- Proprietary site-specific conjugation technologies and novel payloads for ADC development;
-- GMP manufacturing of ADC linkers, payloads & combined linker-payloads; and
-- GMP analytical services for biopharmaceutical manufacturing projects.
For more information, please see www.abzena.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
ACSZMGMVMLKGRZM
(END) Dow Jones Newswires
June 19, 2018 07:28 ET (11:28 GMT)
Abzena (LSE:ABZA)
Historical Stock Chart
From Apr 2024 to May 2024
Abzena (LSE:ABZA)
Historical Stock Chart
From May 2023 to May 2024